Glargine plus Lixisenatide or vildagliptin succeeding to BOT T2DM control evaluation trial in Kobe
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Lixisenatide (Primary) ; Vildagliptin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GLP-ONE-KOBE
- 23 Oct 2018 Status changed from recruiting to completed.
- 01 Oct 2018 Results published in the Diabetes Therapy
- 21 May 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.